According to our latest study on “Cell Line Development Market Forecast to 2027 – COVID-19 Impact and Analysis – by Type, Product, and Application,” the market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027. The report highlights trends prevailing in the global cell line development market, and the drivers and restraints pertaining to the market growth.
The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The increasing investments in R&D by pharmaceutical and biotechnology companies, coupled with increasing adoption of regenerative medicines, are likely to drive the growth of the cell line development market during the forecast period.
Download sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPHE100001196/
Market leaders operating in the market have undertaken various organic growth strategies in the cell line development market. the cell line development market majorly consists of the players Thermo Fisher Scientific Inc., Merck KGaA, Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXi AppTec Group. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
In Europe, economies are severely affected by the exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. Pharmaceutical and MedTech companies are engaged in developing new therapeutics and vaccines for this disease. At the same time, the clinical and product development of other therapeutics has experienced disruption owing to remote work environments, reduced workforce, and supply chain discontinuations. Thus, the ongoing COVID-19 pandemic is likely to limit the growth of the cell line development market for a certain time period.
Based on type, the global cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019. However, the hybridomas segment is anticipated to register the highest CAGR during the forecast period. This growth is attributed to rising research and development activities for novel biologics.
Below is the list of the growth strategies done by the players operating in the cell line development market:
In April, 2019- Lonza introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs.
In June, 2019 - Thermo Fisher Scientific introduced Cytomat 2 C-LiN Series automated incubator for cell cultures. This instrument has features such as automated Controlled humidity, in built contamination reduction system, other advance features.
In October, 2019 - Merck acquired FloDesign Sonics a US based company. FloDesign Sonics is a developer of a unique acoustic cell processing platform that is applicable for the industrialization of cell and gene therapy manufacturing.
Read More@ https://www.theinsightpartners.com/reports/cell-line-development-market
Views similar post@ https://businessfob.com/biocomposites-market-size-share-report-forecast-2022-2028/